Informational only — Not medical advice. Always consult a licensed healthcare provider.

Community data Updated 23 hours ago

Indications

Paliperidone Palmitate is an atypical antipsychotic. It is used for the treatment of schizophrenia in adults. It is also used for the treatment of schizoaffective disorder in adults, either on its own as monotherapy or as an adjunct to mood stabilizers or antidepressants.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Paliperidone palmitate is hydrolyzed to paliperidone, which is the major active metabolite of risperidone. How paliperidone works is not clear. Its effect in schizophrenia could come from a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism.

In vitro, paliperidone acts as an antagonist at the central D2 and 5HT2A receptors. The binding affinities (Ki values) are 1.6-2.8 nM for D2 and 0.8-1.2 nM for 5HT2A receptors. Paliperidone is also active as an antagonist at the α1 and α2 adrenergic receptors and at H1 histaminergic receptors, and this may explain some of the other effects of the drug. It has no affinity for cholinergic muscarinic receptors or for β1 and β2-adrenergic receptors. In vitro, the pharmacological activity of the (+)- and (-)- paliperidone enantiomers is qualitatively and quantitatively similar.

Pregnancy & Breastfeeding

There isn't much published data on paliperidone in human breast milk, but the few reports that exist do show it is present there. Nothing is known about how it affects a breastfed infant, and nothing is known about its effect on milk production.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: For schizophrenia, paliperidone palmitate initiation dosing is 234 mg on Day 1 and 156 mg on Day 8. The monthly maintenance dose is 39 to 234 mg, and the maximum monthly dose is 234 mg. For schizoaffective disorder, the initiation dosing is the same, 234 mg on Day 1 and 156 mg on Day 8. The monthly maintenance dose is 78 to 234 mg, and the maximum monthly dose is 234 mg. The maintenance dose is administered 5 weeks after the first injection. For schizophrenia, the recommended maintenance dose is 117 mg. Some patients may do better on a lower or higher maintenance dose, chosen from the other available strengths (39 mg, 78 mg, 156 mg and 234 mg). The dose is adjusted based on tolerability and/or efficacy, using these strengths. The 39 mg strength was not studied in the long-term schizoaffective disorder study.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.